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Fast track

Detroit’s hub for research and
by Amy Oprean
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ince the U.S. ban on stem cell research was lifted
on March 9, 2009, many pockets of promising
research have sprung up across the country as
scientists scramble to recharge their efforts in a field
that holds tremendous potential.
Through a multitude of funding opportunities
and exceptional expertise, Michigan’s University
Research Corridor – the alliance between Wayne
State University, University of Michigan and
Michigan State University – has positioned the
state to be a major hub for stem cell advancement.
Detroit holds particular promise, housing
both Wayne State University and Stem Cell
Commercialization Center located at TechTown, the
university’s research and technology park. Together,
these entities are creating a gravitational pull for
researchers and stem cell-based businesses around
the world.
“We’ve set the stage not only for Detroit to be a
place of important breakthroughs, but a place where
breakthroughs will see a speedy crossover into the
market and into people’s lives,” said Carol Brenner,
associate professor of physiology in WSU’s School
of Medicine. Brenner is one of Wayne State’s head
stem cell researchers who is looking forward to
advances this hub of innovation will make possible.
“This is the place that I’ve wanted to see research
my entire life,” Brenner said. “We are without
a doubt still in the basic stages of research, but
the possibility of what we can accomplish grows
tremendously when there are this many minds in
one place.”
Having worked in both fertility clinics and
academia, Brenner’s 25 years of experience
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with stem cells have the rare combination of
embryology and basic research. A diverse set of
experts is also what brought her to Wayne State,
where a multidisciplinary group of mitochondrial,
embryonic and basic stem cell biology experts is
one of the few of its kind in the country. The group,
which is headed by Brenner and James Eliason,
Ph.D., associate professor of internal medicine, is
working to develop a new method for inducing
pluripotency that may produce stem cells that
are safe for therapeutics and can be used to
model diseases.

Improving technology
Brenner and the team are focusing on adult
pluripotent stem cells, specialized cells that have
been reprogrammed to take on many of the
characteristics of embryonic stem cells. First formed
in 2006 from mouse cells and in 2007 from human
cells, pluripotent stem cells bypass ethical and legal
issues related to embryonic stem cell research. The
current industry standard for inducing pluripotency
involves using lentiviruses. Although these stem
cells can be very useful in modeling diseases, they
would cause serious defects if put back into
the body.
The group is working on a new method of
inducing pluripotency invented by Jianjun Wang,
Ph.D., associate professor of biochemistry in WSU’s
School of Medicine. Gyula Acsadi, M.D., Ph.D.,
associate professor of pediatrics and Graham
Parker, Ph.D., assistant professor of pediatrics in
WSU’s School of Medicine, have joined Brenner
and Wang in developing a method using “protein
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transduction” instead of viruses to induce
pluripotency, with the goal of producing stem cells
that can be put back into the body for therapeutics.
“Once we successfully develop a method for
producing therapeutic stem cells, the door is open
for making precursors to specific organs, to making
larger quantities of cells needed for therapies
and even getting more use out of bone marrow,”
Brenner said.
With the expertise of Michael Shy, Ph.D.,
professor of neurology in Wayne State’s School
of Medicine, the group is also using pluripotent
stem cells to model neurodegenerative diseases.
Their focus is on the role of mitochondria in the
dysfunction of motor neurons, a phenomenon that
occurs in nearly every neurodegenerative disease.
“We suspect that many neurodegenerative diseases
may share many common pathways that are related
to the dysfunction of motor neurons,” Brenner said.
“Previous studies at WSU suggest that mitochondria
are somehow involved with this dysfunction.”
To start, the team is zeroing in on motor
neuron dysfunction in patients with CharcotMarie Tooth disease, a nerve disorder characterized
by loss of muscle tissue, and Spinal Muscular
Atrophy, a neuromuscular disease characterized
by degeneration of motor neurons. By inducing
pluripotency in cells from people with these
diseases, they will be able to observe the
disease from its very beginning stages through
development, allowing them to not only observe
the role of mitochondria, but to identify biomarkers
and develop a model for the disease.
“Returning the cells back to an embryonic state
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allows us to go back to the early development and
to try to understand the entire process of how the
disease manifests,” Brenner said. “It’s like looking at
an embryo with that disease.”
Getting a foot up on bringing the research into
the next stage, Eliason has also started a company
to commercialize the research. Mitostem, at
TechTown, was formed to commercialize neural
regeneration technology as it’s developed.
The commercialization center, which is headed
by Eliason as executive director, will be a diverse
hub for resources and collaborators that will
accelerate advances in stem cell-based therapies
while stimulating Detroit’s economy through its
role as a stem cell-specific business incubator. Some
businesses have developed their own technology for
things such as bone repair therapy. Many others are
biobanks that facilitate faster research by supplying
stem cells lines or nutrients required for keeping
stem cells alive and healthy.
MitoStem recently received a $200,000 Small
Business Innovation Research Phase I grant from
the National Institute of General Medical Sciences
of the National Institutes of Health to optimize its
revolutionary stem cell technology developed at
Wayne State University. Issued under the American
Recovery and Reinvestment Act of 2009, the grant
will allow researchers to develop new stem cell lines
relevant for a variety of diseases, and enable the
creation of stem cells from patient’s own cells for
replacement of diseased and damaged tissues.
“Growing stem cells is not a trivial thing; it’s
tricky,” Eliason said. “One of the great things about
this center is that it will build up the expertise in
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producing and maintaining good stem cell lines. It
will take a lot of the tedious aspects off scientists’
hands and give them more time to do interesting
research. At the same time, it will allow bio
companies to make a name for themselves in this
area of growing demand, boosting the economy of
Detroit in the process.”
With the multidisciplinary group and
commercialization center up and running, Brenner
sees the coming years being prosperous both in
terms of business growth and in crossing the
threshold from basic stem cell research to clinical
applications that will change people’s lives.
“We’re really getting all the necessary players
in one place to advance basic research and bring it
to the next phase as quickly as possible,” Brenner
said. “It will be incredibly exciting to see where the
innovation takes us.”
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Multidisciplinary stem cell team at
Wayne State University
Wayne State’s unique group of mitochondrial,
embryonic and basic stem cell biology experts are
working to model neurodegenerative diseases with
adult pluripotent stem cells and develop a new
method for inducing pluripotency that could finally
make stem cells safe for therapeutics. Here is a
breakdown of their areas of focus:

Dan Rappolee, Ph.D., associate professor of
obstetrics and gynecology, School of Medicine
http://www.med.wayne.edu/anatomy/department/
Dan.html
n
Creating human stem cell models for neurological
diseases.
Gyula Acsadi, M.D.,Ph.D., associate professor
of pediatrics, School of Medicine
http://neurology.med.wayne.edu/department/

Co-principal investigators:

profile.php?id=1838
Graham Parker, Ph.D., assistant professor of
pediatrics, School of Medicine

in Medford, Mass, and was a post-doctorate in

Carol Brenner, Ph.D., associate professor of
physiology, School of Medicine
http://www.med.wayne.edu/Embryo/Carol%20
Brenner.html
James Eliason Ph.D., associate professor of
internal medicine, School of Medicine and executive
director of MitoStem http://techtownwsu.org/
n
Developing “protein transduction,” a potential
alternative method of inducing pluripotency in adult
stem cells, that does not require lentiviruses.
Jianjun Wang, Ph.D., associate professor of
biochemistry, School of Medicine

molecular embryology at the University of California,

http://www.med.wayne.edu/biochem/BMB_Faculty/

n
Studying stem cells in relation to tissue repair and
regeneration strategies, and in vitro tissue models.
Howard Matthews, Ph.D., professor of
chemical engineering and materials science, College
of Engineering

San Francisco. She joined Wayne State in 2007.

Wang.html

http://www.eng.wayne.edu/che/matthew.htm

About Dr. Carol Brenner:
Dr. Brenner received a B.Sc. in genetics from
Queen Mary College at the University of London, a
Ph.D. in molecular embryology from Tufts University

http://www.med.wayne.edu/crcm/laboratories/
parker.asp
Michael Shy, Ph.D., professor of neurology,
School of Medicine
http://www.genetics.wayne.edu/faculty/
shy/index.php

n
Testing different culture conditions that could
eliminate stress in reprogrammed stem cells.
Randall Armant, Ph.D., professor of obstetrics
and gynecology, School of Medicine
http://www.med.wayne.edu/Anatomy/department/
armant.htm
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